Chemistry:Selvigaltin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | GB1211 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H16BrF3N4O4S |
| Molar mass | 533.32 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Selvigaltin (GB1211) is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered.[1] It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis[2] and resistance to checkpoint inhibitors (a type of anti-cancer drug).[3][4]
References
- ↑ Aslanis, Vassilios; Slack, Robert J.; MacKinnon, Alison C.; McClinton, Catherine; Tantawi, Susan; Gravelle, Lise; Nilsson, Ulf J.; Leffler, Hakon et al. (March 2023). "Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants". Cancer Chemotherapy and Pharmacology 91 (3): 267–280. doi:10.1007/s00280-023-04513-y. ISSN 1432-0843. PMID 36914828.
- ↑ "New Agent Shows Promise in Decompensated Cirrhosis". www.gastroendonews.com. https://www.gastroendonews.com/Hepatology-in-Focus/Article/04-23/Decompensated-Cirrhosis-oral-galectin-3-inhibitor/69945.
- ↑ Ghiringhelli, François; Doucet, Ludovic; Barre, Patricia; Pichon, Eric; Ponce Aix, Santiago; Juan-Vidal, Oscar; Carcereny, Enric; Sethi, Tariq et al. (1 June 2022). "GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.". Journal of Clinical Oncology 40 (16_suppl): TPS9152. doi:10.1200/JCO.2022.40.16_suppl.TPS9152.
- ↑ Mabbitt, Joseph; Roper, James A.; Slack, Robert John (1 June 2022). "Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.". Journal of Clinical Oncology 40 (16_suppl): 2607. doi:10.1200/JCO.2022.40.16_suppl.2607.
 |  |
